Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by AKAMPION

< Previous 1 2 Next >
BellaSeno Presents Novel Production Workflow for Customized, 3D-Printed Bone Scaffolds
From AKAMPION
Via GlobeNewswire
ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002
From AKAMPION
Via GlobeNewswire
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA
From AKAMPION
Via GlobeNewswire
Dopavision Reports Successful Completion of Enrollment for MyopiaX-1 Trial
From AKAMPION
Via GlobeNewswire
Cellbox Solutions Submits Device Master File (DMF) to the U.S. FDA
From AKAMPION
Via GlobeNewswire
1ST Biotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate FB849 in Combination With KEYTRUDA® (pembrolizumab)
From AKAMPION
Via GlobeNewswire
Thermosome Establishes High-Profile Clinical Advisory Board
From AKAMPION
Via GlobeNewswire
ImmunOs Therapeutics Appoints Dr. Constanze Guenther as Senior Vice President, CMC and Technical Development
From AKAMPION
Via GlobeNewswire
BellaSeno Reports Positive One-Year Patient Follow-Up Data for Resorbable Breast and Pectus Excavatum Scaffolds
From AKAMPION
Via GlobeNewswire
TolerogenixX expands Phase II immune-tolerance trial and closes EUR 12 million Series A financing
From AKAMPION
Via GlobeNewswire
BellaSeno Granted Market Access in Europe for Custom-Made Bone and Pectus Excavatum Scaffolds
From AKAMPION
Via GlobeNewswire
Cellbox Solutions GmbH Awarded €2.5 Million Grant Combined with an Equity Component of up to €10 Million Under the European Innovation Council´s Accelerator Program
From AKAMPION
Via GlobeNewswire
Oliver Healthcare Packaging Strengthens Supply Chain, Adds In-Region Film & Foil Production
From AKAMPION
Via GlobeNewswire
Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Active
From AKAMPION
Via GlobeNewswire
BellaSeno Demonstrates Superior Biomechanical Properties of its 3-D Printed, Resorbable Scaffolds for Bone Reconstruction
From AKAMPION
Via GlobeNewswire
Thermosome Announces Participation in IMAGIO Consortium to Improve Cancer Treatment
From AKAMPION
Via GlobeNewswire
MetrioPharm Receives Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy
From AKAMPION
Via GlobeNewswire
selectION, Inc., Reports Interim Safety and Tolerability Results of Phase 1b Clinical Trial in Atopic Dermatitis
From AKAMPION
Via GlobeNewswire
Thermosome Announces First Patient Dosed in Phase I Trial with Lead Program THE001
From AKAMPION
Via GlobeNewswire
ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002
From AKAMPION
Via GlobeNewswire
Pan Cancer T appoints Rachel Abbott to succeed Katrien Reynders-Frederix as Chief Executive Officer
From AKAMPION
Via GlobeNewswire
Positive Interim Data of BellaSeno's Clinical Trial with Resorbable Breast and Chest Implants Reported at RACS 2023
From AKAMPION
Via GlobeNewswire
Omnix Medical Announces Excellent Topline Data from the Phase I Clinical Trial of its Novel Anti-Infective OMN6
From AKAMPION
Via GlobeNewswire
ImmunOs Therapeutics Appoints Michael A. Curran, PhD, as Chairman of its Scientific Advisory Board
From AKAMPION
Via GlobeNewswire
ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
From AKAMPION
Via GlobeNewswire
EBViously Announces First Details of Its EBV-001 Vaccine Candidate for the Prevention of Epstein-Barr Virus (EBV)-Induced Diseases
From AKAMPION
Via GlobeNewswire
InfanDx AG Revises Strategy and Broadens Diagnostics Pipeline for Child Health
From AKAMPION
Via GlobeNewswire
Thermosome Receives Regulatory Approval for First-In-Human Trial with its Lead Program THE001
From AKAMPION
Via GlobeNewswire
HpVac reports positive effects of its lead compound HpVac-R13 in a murine model of allergic asthma following oral administration
From AKAMPION
Via GlobeNewswire
Dopavision Appoints Prof. Dr. Jens Ellrich as Chief Scientific Officer
From AKAMPION
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.